📊

Executive Summary

Preclinical TransCon protein degrader targeting FGF-23 for X-linked hypophosphatemia, a novel approach to reduce excess FGF-23 that causes phosphate wasting

TransCon_FGF-23_degrader

· TransCon protein degrader

Preclinical

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy